BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 12353402)

  • 1. [Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].
    Morozov IA
    Eksp Klin Gastroenterol; 2002; (3):94-100, 122. PubMed ID: 12353402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuing development of acid pump inhibitors: site of action of pantoprazole.
    Shin JM; Besancon M; Prinz C; Simon A; Sachs G
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():11-23. PubMed ID: 7514042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
    Meyer UA
    Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
    Lorentzon P; Bayati A; Lee H; Andersson K
    Ann N Y Acad Sci; 1997 Nov; 834():592-9. PubMed ID: 9405870
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacodynamic effects of 3-day intravenous treatment with pantoprazole or ranitidine after 10 days of oral ranitidine.
    Ley LM; Becker A; Lühmann R; Sander P; Lücker PW
    Methods Find Exp Clin Pharmacol; 2005; 27(1):25-9. PubMed ID: 15834456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
    Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
    Besancon M; Simon A; Sachs G; Shin JM
    J Biol Chem; 1997 Sep; 272(36):22438-46. PubMed ID: 9278394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.
    Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
    Eur J Drug Metab Pharmacokinet; 1998; 23(1):19-26. PubMed ID: 9625268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion.
    Blum RA; Shi H; Karol MD; Greski-Rose PA; Hunt RH
    Clin Ther; 1997; 19(5):1013-23. PubMed ID: 9385488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
    Andersson T; Holmberg J; Röhss K; Walan A
    Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
    Kromer W
    Scand J Gastroenterol Suppl; 2001; (234):3-9. PubMed ID: 11768559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg.
    Florent C; Forestier S
    Eur J Gastroenterol Hepatol; 1997 Feb; 9(2):195-200. PubMed ID: 9058634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
    Takeuchi K; Konaka A; Nishijima M; Kato S; Yasuhiro T
    J Gastroenterol Hepatol; 1999 Mar; 14(3):251-7. PubMed ID: 10197495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of proton pump inhibitors on thyroid hormone metabolism in rats: a comparison of UDP-glucuronyltransferase induction.
    Masubuchi N; Hakusui H; Okazaki O
    Biochem Pharmacol; 1997 Dec; 54(11):1225-31. PubMed ID: 9416973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.
    Dilger K; Zheng Z; Klotz U
    Br J Clin Pharmacol; 1999 Sep; 48(3):438-44. PubMed ID: 10510158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ranitidine, famotidine, pantoprazole, and omeprazole on intragastric pH in dogs.
    Bersenas AM; Mathews KA; Allen DG; Conlon PD
    Am J Vet Res; 2005 Mar; 66(3):425-31. PubMed ID: 15822586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
    Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
    Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis or rupture: duration of acid inhibition by proton pump inhibitors.
    Sachs G; Shin JM; Pratha V; Hogan D
    Drugs Today (Barc); 2003 Mar; 39 Suppl A():11-4. PubMed ID: 12712216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.